Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 5 of 5

Full-Text Articles in Medicine and Health Sciences

Program Active Ii: Design And Methods For A Multi-Center Community-Based Depression Treatment For Rural And Urban Adults With Type 2 Diabetes, Mary De Groot, Jay H. Shubrook, Frank Schwartz, W. Guyton Hornsby Jr., Yegan Pillay, Chandan Saha Jan 2015

Program Active Ii: Design And Methods For A Multi-Center Community-Based Depression Treatment For Rural And Urban Adults With Type 2 Diabetes, Mary De Groot, Jay H. Shubrook, Frank Schwartz, W. Guyton Hornsby Jr., Yegan Pillay, Chandan Saha

Faculty Publications & Research of the TUC College of Osteopathic Medicine

Objective: Depression affects one in four adults with type 2 diabetes (T2DM) and is associated with worsened diabetes complications, increased health care costs and early mortality. Rural and low-income urban areas, including the Appalachian region, represent an epicenter of the T2DM epidemic. Program ACTIVE II is a comparative effectiveness treatment trial designed to test whether a combination of cognitive behavioral therapy (CBT) and community-based exercise (EXER) will offer greater improvements in diabetes and depression outcomes compared to individual treatment approaches and usual care (UC). The secondary aims are to assess changes in cardiovascular risk factors across groups and to …


Sglt2 Inhibitors For Type 2 Diabetes Mellitus Treatment, Raymond A. Plodkowski, Megan E. Mcgarvey, Heather M. Huribal, Keith Reisinger-Kindle, Bradley Kramer, Mordecai Solomon, Quang T. Nguyen Jan 2015

Sglt2 Inhibitors For Type 2 Diabetes Mellitus Treatment, Raymond A. Plodkowski, Megan E. Mcgarvey, Heather M. Huribal, Keith Reisinger-Kindle, Bradley Kramer, Mordecai Solomon, Quang T. Nguyen

College of Osteopathic Medicine (TUN) Publications and Research

SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effects while inducing weight loss without hypoglycemia.


Treating The Cognitive And Social Dysfunctions Related To Type 2 Diabetes, Joseph Indelicato Jan 2015

Treating The Cognitive And Social Dysfunctions Related To Type 2 Diabetes, Joseph Indelicato

The School of Health Sciences Publications and Research

While much has been written about the effects of diabetes on cardiovascular functioning, less attention has been paid upon the role of diabetes on cognitive functioning. While researchers are still debating the pathophysiology of the cognitive dysfunction triggered by diabetes, including the possibility that Alzheimer’s being Type III diabetes, among other possibilities. Less research has targeted addressing these problems among those with diabetes. Social problems associated with having cognitive dysfunctions in diabetics, have received very little attention. Social activities are perhaps the most difficult and complicated behaviors humans engage in, Even the concept of measurable Social Intelligence comes relatively new …


Empagliflozin In The Treatment Of Type 2 Diabetes: Evidence To Date, Jay H. Shubrook, Babak Baradar Bokaie, Sarah E. Adkins Jan 2015

Empagliflozin In The Treatment Of Type 2 Diabetes: Evidence To Date, Jay H. Shubrook, Babak Baradar Bokaie, Sarah E. Adkins

Faculty Publications & Research of the TUC College of Osteopathic Medicine

In the last decade, researchers have gained a greater understanding of the pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes by increasing the reabsorption of glucose above the normal physiologic renal threshold. This discovery has led to the development of the sodium/glucose cotransporter 2 inhibitors (SGLT2). These agents readjust the renal threshold for glucose reabsorption to a lower level and decrease glucose reabsorption, while increasing urinary glucose when the glucose is above the renal threshold and subsequently lowering plasma glucose. …


What To Do After Basal Insulin: 3 Tx Strategies For Type 2 Diabetes, Lubaina Presswala, Jay H. Shubrook Jan 2015

What To Do After Basal Insulin: 3 Tx Strategies For Type 2 Diabetes, Lubaina Presswala, Jay H. Shubrook

Faculty Publications & Research of the TUC College of Osteopathic Medicine

While many family physicians have become comfortable with using once-daily basal insulin such as glargine or detemir, what to do after basal insulin is much more complex. This review builds upon an earlier article in this journal, “Insulin for type 2 diabetes: How and when to get started,” by explaining 3 strategies to consider when basal insulin alone isn't enough.